Sanofi Archives -

News/ News/ News/ Patients/ Sales and Marketing

GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’

Phil Taylor GlaxoSmithKline, Haleon, litigation, Pfizer, safety, Sanofi, Zantac 0 Comment

GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in

GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’

https://pharmaphorum.com/news/gsk-sanofi-and-haleon-facing-billions-of-dollars-in-zantac-liability/

xray image of human head with brain and electric pulses

News/ News/ R&D

Sanofi pauses enrolment in ex-US tolebrutinib trials

Phil Taylor BTK inhibitor, evobrutinib, Merck KGaA, multiple sclerosis, safety, Sanofi 0 Comment

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although

Sanofi pauses enrolment in ex-US tolebrutinib trials

https://pharmaphorum.com/news/sanofi-pauses-enrolment-in-ex-us-tolebrutinib-trials/

Digital/ Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

AI tissue analysis enables rapid discovery of drug candidates

Ben Hargreaves AI, AI drug discovery, Bristol-Myers Squibb, drug discovery, exscientia, Owkin, Sanofi 0 Comment

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential

AI tissue analysis enables rapid discovery of drug candidates

https://pharmaphorum.com/digital/ai-tissue-analysis-enables-rapid-discovery-of-drug-candidates/

News/ News/ News/ Patients/ Sales and Marketing

Bayer tops pharma rankings for diversity, inclusivity

Phil Taylor alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva 0 Comment

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women

Bayer tops pharma rankings for diversity, inclusivity

https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/

Market Access/ News/ News/ News/ Oncology

Sanofi looks east with €300m Innovent cancer alliance

Phil Taylor China, immuno-oncology, Innovent, Oncology, partnering, Sanofi, sintilimab, tusamitamab ravtansine 0 Comment

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring

Sanofi looks east with €300m Innovent cancer alliance

https://pharmaphorum.com/news/sanofi-looks-east-with-e300m-innovent-cancer-alliance/

News/ News/ R&D

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Phil Taylor China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax 0 Comment

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire

Chinese biotech Sironax raises $200m for RIPK1 pipeline

https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/

News/ News/ Sales and Marketing

Dupixent drives Sanofi to hike its full-year profit forecasts

Phil Taylor Dupixent, Financial, immunology, Sanofi 0 Comment

Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second

Dupixent drives Sanofi to hike its full-year profit forecasts

https://pharmaphorum.com/news/dupixent-drives-sanofi-to-hike-its-full-year-profit-forecasts/

News/ News/ R&D

Sanofi trumpets data with haemophilia treatment duo at ISTH

Phil Taylor Alnylam Pharmaceuticals, haemophilia, Hemlibra, Roche, Sanofi, SOBI 0 Comment

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs

Sanofi trumpets data with haemophilia treatment duo at ISTH

https://pharmaphorum.com/news/sanofi-trumpets-data-with-haemophilia-treatment-duo-at-isth/

News/ News/ Sales and Marketing

Sanofi makes low-cost medicines pledge for low-income countries

Phil Taylor access, developing world, Pfizer, pricing, Sanofi 0 Comment

Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to

Sanofi makes low-cost medicines pledge for low-income countries

https://pharmaphorum.com/news/sanofi-makes-low-cost-medicines-pledge-for-low-income-countries/

Trending

Sanofi

Login